— Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, Intermediate Capital Group (ICG), Tybourne Capital Management, Aisling Capital Management, and other top-tier life sciences investors — — Proceeds will fund the ongoing pivotal T-RRex trial in relapsed/refractory T-ALL/T-LBL — — WU-CART-007 achieved 91% overall...
